Dr. Omar Ziad Ameer Al Adhami

Assistant Professor of Pharmacology & Physiology

Bio

Add
Assistant Professor of Physiology and Pharmacology

 Dr Ameer is a physio-pharmacologist researcher. He trained initially as a pharmacist, and after a number of years of working as a clinical pharmacist in hospitals & community pharmacies, went on to do an MSc in pharmacology, followed by a PhD in Advanced Medicine from at the Australian School of Advanced Medicine, and a post-doc at Case Western Reserve University, Cleveland. During his career, Dr Ameer, developed a real passion for teaching and research within various international universities ranging from Malaysia, Australia, the US and KSA. Dr Ameer has significant research records of accomplishment and awards within the area of physiology, pharmacology and neuroscience from countries like Malaysia, South Korea, Germany, Australia and the US. Currently, he is a faculty member at the College of Pharmacy and the Head of the Department of Pharmaceutical Sciences, Alfaisal University. Dr Ameer's research interests and areas of expertise fall within the mechanisms of antihypertensive drugs, blood pressure and heart rate and their relation to kidney function, arterial function, engineering elastic modulus and stiffness with its connection to overall cardiovascular health.  The influence of sympathetic and parasympathetic control of arterial pressure, endothelium-dependent and independent vascular mechanisms, in health and metabolic syndrome and finally, the neurocircuitry involvement in salivary gland secretion and modulations by the cervical sympathetic chain. Dr Ameer's scientific track records involves a published book and over 50 peer-reviewed journal articles, scored over 1000 citations (Google Scholar) and accumulated over 30.000 reads on (Research Gate).

 

Assistant Professor Omar Z Ameer

Publications

Add

In-vitro pharmaco-equivalence analysis of diclofenac potassium oral film coated tablet relative to marketed generics

Journal Article ,
Ameer, O. Z. (2023). In-vitro pharmaco-equivalence analysis of diclofenac potassium oral film coated tablet relative to marketed generics. Journal Of Pharmacy And Pharmacognosy Research.

Release Profile of Branded Atorvastatin Calcium Tablet Relative to Commercially Available Counterpart Generics. Dissolution technologies

Journal Article ,
Ameer, O. Z. (2023). Release Profile of Branded Atorvastatin Calcium Tablet Relative to Commercially Available Counterpart Generics. Dissolution technologies. Dissolution Technologies.

Role of vascular functional and structural alterations in the development and maintenance of hypertension in chronic kidney disease

Journal Article ,
Role of vascular functional and structural alterations in the development and maintenance of hypertension in chronic kidney disease. (2022). Role of vascular functional and structural alterations in the development and maintenance of hypertension in chronic kidney disease. Macquarie University, 2022.

Hypertension in chronic kidney disease: What lies behind the scene

Journal Article ,
Ameer, O. Z. (2022). Hypertension in chronic kidney disease: What lies behind the scene. Frontiers In Pharmacology, 13(13), 28. (Original work published 2022)

KI-67 LI Expression in Triple-Negative Breast Cancer Patients and Its Significance

Journal Article ,
KI-67 LI Expression in Triple-Negative Breast Cancer Patients and Its Significance. (2021). KI-67 LI Expression in Triple-Negative Breast Cancer Patients and Its Significance. Breast Cancer: Basic And Clinical Research 15, 11782234211016977, 2021.

Amlodipine improves vessel function and remodeling in the lewis polycystic kidney rat mesenteric artery

Journal Article ,
Amlodipine improves vessel function and remodeling in the lewis polycystic kidney rat mesenteric artery. (2020). Amlodipine improves vessel function and remodeling in the lewis polycystic kidney rat mesenteric artery. American Journal Of Hypertension 33 (7), 634-643, 2020.

SHOULD WE TREAT AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY DISEASE WITH AMLODIPINE?

Journal Article ,
SHOULD WE TREAT AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY DISEASE WITH AMLODIPINE?. (2020). SHOULD WE TREAT AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY DISEASE WITH AMLODIPINE?. Nephrology 25, 26-26, 2020.

Amlodipine improves vessel function and remodelling in the Lewis Polycystic Kidney rat mesenteric artery

Journal Article ,
Amlodipine improves vessel function and remodelling in the Lewis Polycystic Kidney rat mesenteric artery. (2020). Amlodipine improves vessel function and remodelling in the Lewis Polycystic Kidney rat mesenteric artery. American Journal Of Hypertension.

AT1 Receptor Antagonism Improves Structural, Functional and Biomechanical Properties in Resistance Arteries in a Rodent Chronic Kidney Disease Model

Journal Article ,
AT1 Receptor Antagonism Improves Structural, Functional and Biomechanical Properties in Resistance Arteries in a Rodent Chronic Kidney Disease Model. (2018). AT1 Receptor Antagonism Improves Structural, Functional and Biomechanical Properties in Resistance Arteries in a Rodent Chronic Kidney Disease Model. American Journal Of Hypertension, 7(6), 696-705.

AT1 Receptor Antagonism Improves Structural, Functional, and Biomechanical Properties in Resistance Arteries in a Rodent Chronic Kidney Disease Model

Journal Article ,
AT1 Receptor Antagonism Improves Structural, Functional, and Biomechanical Properties in Resistance Arteries in a Rodent Chronic Kidney Disease Model. (2018). AT1 Receptor Antagonism Improves Structural, Functional, and Biomechanical Properties in Resistance Arteries in a Rodent Chronic Kidney Disease Model. American Journal Of Hypertension 31 (6), 696-705, 2018, 31, 696–705.

Long-term angiotensin II receptor blockade limits hypertension, aortic dysfunction and structural remodelling in a rat model of chronic kidney disease

Journal Article ,
Long-term angiotensin II receptor blockade limits hypertension, aortic dysfunction and structural remodelling in a rat model of chronic kidney disease. (2016). Long-term angiotensin II receptor blockade limits hypertension, aortic dysfunction and structural remodelling in a rat model of chronic kidney disease. Journal Of Vascualr Reserach, 53(3-4), 216-229.

Progressive vascular remodelling, endothelial dysfunction and stiffness in mesenteric resistance arteries in a rodent model of chronic kidney disease

Journal Article ,
Progressive vascular remodelling, endothelial dysfunction and stiffness in mesenteric resistance arteries in a rodent model of chronic kidney disease. (2016). Progressive vascular remodelling, endothelial dysfunction and stiffness in mesenteric resistance arteries in a rodent model of chronic kidney disease. Vascular Pharmacology 81, 42-52, 2016, 81(7), 42-52.

Progressive vascular remodelling, endothelial dysfunction and stiffness in mesenteric resistance arteries in a rodent model of chronic kidney disease

Journal Article ,
Progressive vascular remodelling, endothelial dysfunction and stiffness in mesenteric resistance arteries in a rodent model of chronic kidney disease. (2016). Progressive vascular remodelling, endothelial dysfunction and stiffness in mesenteric resistance arteries in a rodent model of chronic kidney disease. Vascular Pharmacology, 81, 42–52.

Long-term angiotensin II receptor blockade limits hypertension, aortic dysfunction, and structural remodeling in a rat model of chronic kidney disease

Journal Article ,
Long-term angiotensin II receptor blockade limits hypertension, aortic dysfunction, and structural remodeling in a rat model of chronic kidney disease. (2016). Long-term angiotensin II receptor blockade limits hypertension, aortic dysfunction, and structural remodeling in a rat model of chronic kidney disease. Journal Of Vascular Research 53 (3-4), 216-229, 2016, 53, 216–229.

Abnormalities associated with progressive aortic vascular dysfunction in chronic kidney disease

Journal Article ,
Abnormalities associated with progressive aortic vascular dysfunction in chronic kidney disease. (2015). Abnormalities associated with progressive aortic vascular dysfunction in chronic kidney disease. Frontiers In Physiology 6, 150, 2015, 6(150).

Protective cardiorenal effects of spironolactone in a rodent model of polycystic kidney disease

Journal Article ,
Protective cardiorenal effects of spironolactone in a rodent model of polycystic kidney disease. (2015). Protective cardiorenal effects of spironolactone in a rodent model of polycystic kidney disease. Clinical And Experimental Pharmacology And Physiology 42 (4), 353-360, 2015, 4, 353-360.

High blood pressure as a driver of structural and biomechanical changes in mesenteric resistance arteries in chronic kidney disease

Journal Article ,
High blood pressure as a driver of structural and biomechanical changes in mesenteric resistance arteries in chronic kidney disease. (2015). High blood pressure as a driver of structural and biomechanical changes in mesenteric resistance arteries in chronic kidney disease. United States: Lippincott Williams & Wilkins, 2015.

Abnormalities associated with progressive aortic vascular dysfunction in chronic kidney disease

Journal Article ,
Abnormalities associated with progressive aortic vascular dysfunction in chronic kidney disease. (2015). Abnormalities associated with progressive aortic vascular dysfunction in chronic kidney disease. Frontiers In Physiology, 6, 150.

Sympathetic overactivity prevails over the vascular amplifier phenomena in a chronic kidney disease rat model of hypertension

Journal Article ,
Sympathetic overactivity prevails over the vascular amplifier phenomena in a chronic kidney disease rat model of hypertension. (2014). Sympathetic overactivity prevails over the vascular amplifier phenomena in a chronic kidney disease rat model of hypertension. Physiological Reports 2 (11), E12205, 2014, 11(12205).

). Differential contribution of afferent and central pathways to the development of baroreflex dysfunction in chronic kidney disease

Journal Article ,
). Differential contribution of afferent and central pathways to the development of baroreflex dysfunction in chronic kidney disease. (2014). ). Differential contribution of afferent and central pathways to the development of baroreflex dysfunction in chronic kidney disease. Hypertension, 63, 804-810.

Altered structural and biomechanical properties of mesenteric resistance arteries in a rat model of cystic kidney disease

Journal Article ,
Altered structural and biomechanical properties of mesenteric resistance arteries in a rat model of cystic kidney disease. (2014). Altered structural and biomechanical properties of mesenteric resistance arteries in a rat model of cystic kidney disease. Journal Of Vascular Research 51 (Supplement 2), 115-115, 2014.

Opposing changes in thoracic and abdominal aortic biomechanical properties in rodent models of vascular calcification and hypertension

Journal Article ,
Opposing changes in thoracic and abdominal aortic biomechanical properties in rodent models of vascular calcification and hypertension. (2014). Opposing changes in thoracic and abdominal aortic biomechanical properties in rodent models of vascular calcification and hypertension. American Journal Of Physiology-Heart And Circulatory Physiology, 307, H143–H151.

Sympathetic overactivity prevails over the vascular amplifier phenomena in a chronic kidney disease rat model of hypertension

Journal Article ,
Sympathetic overactivity prevails over the vascular amplifier phenomena in a chronic kidney disease rat model of hypertension. (2014). Sympathetic overactivity prevails over the vascular amplifier phenomena in a chronic kidney disease rat model of hypertension. Physiological Reports, 2, e12205.

Antioxidant, antiangiogenic and vasorelaxant activities of methanolic extract of Clerodendrum serratum (Spreng.) leaves

Journal Article ,
Antioxidant, antiangiogenic and vasorelaxant activities of methanolic extract of Clerodendrum serratum (Spreng.) leaves. (2012). Antioxidant, antiangiogenic and vasorelaxant activities of methanolic extract of Clerodendrum serratum (Spreng.) leaves. Journal Of Medicinal Plants Research 6 (3), 348-360, 2012.

1037 INHIBITION OF THE RENIN ANGIOTENSIN ALDOSTERONE SYSTEM AND ITS IMPACT ON KIDNEY OXIDATIVE STRESS, RENAL FUNCTION AND HYPERTENSION IN POLYCYSTIC KIDNEY DISEASE

Journal Article ,
1037 INHIBITION OF THE RENIN ANGIOTENSIN ALDOSTERONE SYSTEM AND ITS IMPACT ON KIDNEY OXIDATIVE STRESS, RENAL FUNCTION AND HYPERTENSION IN POLYCYSTIC KIDNEY DISEASE. (2012). 1037 INHIBITION OF THE RENIN ANGIOTENSIN ALDOSTERONE SYSTEM AND ITS IMPACT ON KIDNEY OXIDATIVE STRESS, RENAL FUNCTION AND HYPERTENSION IN POLYCYSTIC KIDNEY DISEASE. Journal Of Hypertension 30, E302, 2012.

The influence of spironolactone on renal function and cardiovascular disease in polycystic kidney disease

Journal Article ,
The influence of spironolactone on renal function and cardiovascular disease in polycystic kidney disease. (2012). The influence of spironolactone on renal function and cardiovascular disease in polycystic kidney disease. Hypertension 60 (2), 490-490, 2012.

Regional biomechanical properties of the aorta in polycystic kidney disease rats

Journal Article ,
Regional biomechanical properties of the aorta in polycystic kidney disease rats. (2012). Regional biomechanical properties of the aorta in polycystic kidney disease rats. Hypertension 60 (2), 501-501, 2012.

Orthosiphon stamineus: Traditional Uses, Phytochemistry, Pharmacology, and Toxicology

Journal Article ,
Orthosiphon stamineus: Traditional Uses, Phytochemistry, Pharmacology, and Toxicology. (2012). Orthosiphon stamineus: Traditional Uses, Phytochemistry, Pharmacology, and Toxicology. Journal Of Medicinal Food 15 (8), 678-690, 2012.

Characterization of Loranthus ferrugineus cardiovascular activities An ethnopharmacological and phytochemical investigation

Book ,
Characterization of Loranthus ferrugineus cardiovascular activities An ethnopharmacological and phytochemical investigation (p. 288). (2011). Characterization of Loranthus ferrugineus cardiovascular activities An ethnopharmacological and phytochemical investigation (p. 288). In (p. 288). Berlin: LAMBERT Academic Publishing.

In vivo anti-inflammatory and in vitro antioxidant activities of Peperomia pellucida

Journal Article ,
In vivo anti-inflammatory and in vitro antioxidant activities of Peperomia pellucida. (2010). In vivo anti-inflammatory and in vitro antioxidant activities of Peperomia pellucida. Int J Pharmacol 6 (5), 686-90, 2010.

Cardiovascular Activities Of Loranthus Ferrugineus Roxb. Methanol Extract And Its Fractions [RS1-441].

Journal Article ,
Cardiovascular Activities Of Loranthus Ferrugineus Roxb. Methanol Extract And Its Fractions [RS1-441]. (2009). Cardiovascular Activities Of Loranthus Ferrugineus Roxb. Methanol Extract And Its Fractions [RS1-441]. Universiti Sains Malaysia, 2009.

In-vitro vascular reactivity and response to chronic inhibition of aldosterone in the thoracic aorta of polycystic kidney disease rats

Journal Article ,
In-vitro vascular reactivity and response to chronic inhibition of aldosterone in the thoracic aorta of polycystic kidney disease rats. In-vitro vascular reactivity and response to chronic inhibition of aldosterone in the thoracic aorta of polycystic kidney disease rats.

TEMPORAL IMPAIRMENT OF AORTIC ENDOTHELIAL AND VASCULAR SMOOTH MUSCLE FUNCTIONS IN AUTOSOMAL RECESSIVE CYSTIC KIDNEY DISEASE

Journal Article ,
TEMPORAL IMPAIRMENT OF AORTIC ENDOTHELIAL AND VASCULAR SMOOTH MUSCLE FUNCTIONS IN AUTOSOMAL RECESSIVE CYSTIC KIDNEY DISEASE. TEMPORAL IMPAIRMENT OF AORTIC ENDOTHELIAL AND VASCULAR SMOOTH MUSCLE FUNCTIONS IN AUTOSOMAL RECESSIVE CYSTIC KIDNEY DISEASE.

Presentations

Add
No Presentation added

Calendar

Add
No Event Found

Announcements

Add
No Announcement Found

Classes

Add
No Content Added